February 13th 2023
Although trilaciclib appears to reduce neutropenia following treatment with FOLFOXIRI and bevacizumab in patients with metastatic colorectal cancer, the phase 3 PRESERVE 1 trial will be stopped due to a lack of responses.
Community Practice Connections™: Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
View More
2nd Annual Virtual Tumor Board®: Integrating Emerging Testing Methodologies into Optimal Treatment Planning in Gastrointestinal Cancers
View More
Community Practice Connections™: 19th Annual Meeting of the International Society of Gastrointestinal Oncology®
View More
20th Annual Meeting of the International Society of Gastrointestinal Oncology®
10/13/2023-10/14/2023
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
View More
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
View More
Medical Crossfire®: Multidisciplinary Strategies to Leverage Clinical Advances on Immune-Based Therapies for Patients with Hepatocellular Carcinoma
View More
8th Annual School of Gastrointestinal Oncology® (SOGO®)
05/06/23 8:00 AM – 5:00 PM EDT
View More
Expert Illustrations & Commentaries™: Targeting FGFR2b Overexpression in Advanced Gastric and GEJ Cancers
View More
Community Practice Connections™: Analyzing the Evolving Role of Liquid Biopsies Across Cancer Care
View More
Clinical Vignettes™: Testing and Treatment Strategies in Cholangiocarcinoma
View More
Advances In™: The Role of NRG1 Fusions Across Tumor Types
View More
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
View More
Community Practice Connections™: 7th Annual School of Gastrointestinal Oncology®
View More
Addressing Racial and Ethnic Disparities in Breast Cancer Care: Improving Outcomes Across the Spectrum of Diagnosis, Trial Access, and Patient Care
View More
Molecular Profiling for Metastatic Colorectal Cancer and the Future of the Disease
September 25th 2020According to researchers, a “better understanding of the heterogeneity of mCRC, including primary tumor location, microsatellite instability (MSI) status, and other clinically actionable tumor mutations, is reshaping the therapeutic landscape.”
Frontline Pembrolizumab Improves Health-Related QOL in DNA Repair-Deficient Metastatic CRC
September 19th 2020Frontline pembrolizumab induced clinically meaningful improvements in the health-related quality of life of patients with microsatellite instability-high and/or mismatch repair-deficient metastatic colorectal cancer.
Culturally Specific Education Program Improved Knowledge and Screening Rates for CRC
May 12th 2020A recent study implemented the Screen to Save program to educate racial/ethnic minority groups on colorectal cancer, finding that knowledge and screenings increased after patients completed the educational program.
Henry Adewoye, MD, on the Phase I Trial of COM701 in Advanced Solid Tumors
April 30th 2020The study was presented at the American Association for Cancer Research (AACR) Annual Virtual Meeting 2020 and demonstrated encouraging preliminary antitumor activity with objective responses as a monotherapy and in combination with nivolumab.
Experts Issue Recommendations for Patients with Rectal Cancer During the COVID-19 Pandemic
April 10th 2020Leading cancer experts from across Europe issued an international expert consensus statement regarding radiotherapy treatment options for patients with rectal cancer during the COVID-19 pandemic.
Pembrolizumab Induces Significantly Improved PFS in MSI-H/dMMR Colorectal Cancer
April 3rd 2020The trial evaluating the first-line treatment of pembrolizumab in patients with microsatellite instability-high or mismatch repair deficient unresectable or metastatic colorectal cancer demonstrated improved PFS compared with chemotherapy.